News headlines about Sinovac Biotech (NASDAQ:SVA) have been trending somewhat positive recently, according to AlphaOne Sentiment. AlphaOne, a service of Accern, scores the sentiment of news coverage by reviewing more than 20 million news and blog sources in real time. AlphaOne ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Sinovac Biotech earned a news sentiment score of 0.10 on AlphaOne’s scale. AlphaOne also gave headlines about the biopharmaceutical company an impact score of 100 out of 100, indicating that recent news coverage is extremely likely to have an effect on the company’s share price in the next few days.

Insider Buying and Selling by Quarter for Sinovac Biotech (NASDAQ:SVA)

Sinovac Biotech (NASDAQ SVA) traded up 0.56% during trading on Friday, hitting $5.40. The stock had a trading volume of 197,929 shares. The stock’s market cap is $307.63 million. The firm has a 50 day moving average of $5.23 and a 200-day moving average of $5.65. Sinovac Biotech has a 12 month low of $4.60 and a 12 month high of $6.45.

TRADEMARK VIOLATION NOTICE: This news story was posted by Watch List News and is owned by of Watch List News. If you are accessing this news story on another website, it was stolen and republished in violation of US and international trademark & copyright legislation. The legal version of this news story can be viewed at

About Sinovac Biotech

Sinovac Biotech Ltd. (Sinovac) is a holding company. The Company is a biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases, including hepatitis A, hepatitis B, seasonal influenza, Haemagglutinase5 Neuraminidase1 (H5N1) and Influenza A (H1N1) pandemic influenza and mumps.

Receive News & Ratings for Sinovac Biotech Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sinovac Biotech Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.